

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE  
02 FEB 14 PM 3:

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <b>Amgen Inc.</b>			
2. Address <input type="checkbox"/> Check if different than previously reported <b>1300 Eye Street, NW; Suite 470 East</b>			
3. Principal Place of Business (if different from line 2)  City: <b>Washington</b> State/Zip (or Country) <b>DC 20005</b>			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
<b>L. Nicole Antorcha</b>	<b>202/354-6112</b>	<b>nickiea@amgen.com</b>	<b>3867-12</b>
7. Client Name <input type="checkbox"/> Self			6. House ID #
			<b>31560000</b>

**TYPE OF REPORT** 8. Year  Midyear (January 1-June 30) OR  Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying Activity

<b>INCOME OR EXPENSES - Complete Either Line 12 OR Line 13</b>	
<p><b>12. Lobbying Firms</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 \$10,000 or more <input type="checkbox"/> \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p><b>EXPENSES</b> relating to lobbying activities for this report were:</p> <p>Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> \$ <u>1,540,000</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions <input type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>

Signature *Rita E. [Signature]* Date 2/13/02

Printed Name and Title Rita E. Norton, Vice President of Government Relations



Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Medicare Prescription Drug Benefit; Medicare Reimbursement

Implementation of sections 1861(s)(2), 1881(b)(11)(B), and 1833(t)(6) of the Social Security Act

Reimportation of Pharmaceuticals

S. 1135: Medicare Reform Act of 2001

S. 358: Medicare Prescription Drug and Modernization Act of 2001


17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate  
Executive Office of the President

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above   Check if None

Signature  Date 2/13/02

Printed Name and Title Rita E. Norton, Vice President of Government Relations



Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code MMM (one per page)

**16. Specific lobbying issues**

Medicare Prescription Drug Benefit; Medicare Reimbursement

Implementation of sections 1861(s)(2), 1881(b)(11)(B), and 1833(t)(6) of the Social Security Act

Reimportation of Pharmaceuticals

S. 1135: Medicare Reform Act of 2001

S. 358: Medicare Prescription Drug and Modernization Act of 2001

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate  
Executive Office of the President  
Centers for Medicare and Medicaid Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
Judi A. Teske	
Andrew Swire	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature 

Date 2/13/02

Printed Name and Title Rita E. Norton, Vice President of Government Relations



Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

**16. Specific lobbying issues**

Research and Development Tax Credit (no bill numbers apply)

Puerto Rico Tax Credit (no bill numbers apply)

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above   Check if None

Signature 

Date 12/13/02

Printed Name and Title  Rita E. Norton, Vice President of Government Relations



Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code CPT (one per page)

**16. Specific lobbying issues**

Patent Issues Relevant to Hatch-Waxman Reform


**17. House(s) of Congress and Federal agencies contacted**  Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above   Check if None

Signature  Date 12/13/02

Printed Name and Title Rita E. Norton, Vice President of Government Relations

